Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Nurix Therapeutics (NRIX) EPS (Weighted Average and Diluted): 2021-2024

Historic EPS (Weighted Average and Diluted) for Nurix Therapeutics (NRIX) over the last 4 years, with Nov 2024 value amounting to -$2.88.

  • Nurix Therapeutics' EPS (Weighted Average and Diluted) fell 53.73% to -$1.03 in Q3 2025 from the same period last year, while for Aug 2025 it was -$2.97, marking a year-over-year decrease of 2.06%. This contributed to the annual value of -$2.88 for FY2024, which is 8.68% down from last year.
  • Nurix Therapeutics' EPS (Weighted Average and Diluted) amounted to -$2.88 in FY2024, which was down 8.68% from -$2.65 recorded in FY2023.
  • In the past 5 years, Nurix Therapeutics' EPS (Weighted Average and Diluted) registered a high of -$2.65 during FY2023, and its lowest value of -$3.71 during FY2022.
  • In the last 3 years, Nurix Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$2.88 in 2024 and averaged -$3.08.
  • As far as peak fluctuations go, Nurix Therapeutics' EPS (Weighted Average and Diluted) tumbled by 35.90% in 2022, and later increased by 28.57% in 2023.
  • Over the past 4 years, Nurix Therapeutics' EPS (Weighted Average and Diluted) (Yearly) stood at -$2.73 in 2021, then slumped by 35.90% to -$3.71 in 2022, then climbed by 28.57% to -$2.65 in 2023, then decreased by 8.68% to -$2.88 in 2024.